PD-L1 gene expression in Japanese lung cancer patients

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immune dysregulation impacts anti-tumor T-cell responses in the tumor microenvironment.
• Targeting immune checkpoints has shown promise in preclinical cancer models.
• Understanding programmed cell death 1 ligand 1 (PD-L1) expression is crucial for NSCLC treatment strategies.

Purpose of the Study:

• To investigate programmed cell death 1 ligand 1 (PD-L1) mRNA expression in non-small cell lung cancer (NSCLC) tissues.
• To analyze the correlation between PD-L1 mRNA levels and clinicopathological factors in NSCLC.
• To evaluate PD-L1 as a potential therapeutic target in NSCLC.

Main Methods:

• Real-time polymerase chain reaction (RT-PCR) was used to quantify PD-L1 mRNA levels.
• Analysis was performed on 123 surgically resected NSCLC tissues and adjacent normal lung tissues.
• Tumor/normal (T/N) ratios of PD-L1/β-actin mRNA were calculated and compared.

Main Results:

• PD-L1 mRNA levels showed no significant difference between NSCLC and normal lung tissues (P=0.1482).
• The T/N ratio of PD-L1 mRNA was significantly higher in pathological T4 stage tumors compared to T1 stage tumors (P=0.0235).
• PD-L1 mRNA expression did not correlate with gender, age, smoking status, pathological subtypes, or lymph node metastasis.

Conclusions:

• While overall PD-L1 mRNA levels are similar in NSCLC and normal tissues, its increased expression in advanced stages suggests a role in tumor invasion.
• PD-L1 may serve as a potential therapeutic target for antagonizing NSCLC progression.
• Further research is warranted to explore the functional role of PD-L1 in NSCLC invasion and metastasis.